Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Abirateron (ausgenommen Wirkstärke 500mg), ATC L02BX03 f. d. Z. 01.10.26-31.12.27 (zzgl. V.-Option 1x12 Mon)

Section 130a paragraph 8 of the SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance companies. With regard to the relevant legal provisions for the award of public contracts, the DAK-Gesundheit regularly carries out substance-specific, formal tendering procedures in accordance with the regulations of Part 4 of the GWB. For medicines to be specified by the bidder in more detail in Annex 2 to the contract for the aforementioned substance Abiraterone (excluding strength 500 mg), ATC L02BX03, the DAK-Gesundheit intends to conclude pharmaceutical discount contracts with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical discount contracts. A discount contract under the approval model for the aforementioned substance will come into force for the first time on 01.10.2026 and will end on 31.12.2027 (plus extension option 1x12 months). It will automatically end with the entry into force of the exclusive contract, regardless.